Advertisement

Topics

Latest "Kiniksa Pharmaceuticals" News Stories

06:20 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Kiniksa Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Kiniksa Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Kiniksa Pharmaceuticals for you to read. Along with our medical data and news we also list Kiniksa Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Kiniksa Pharmaceuticals Companies for you to search.

Showing "Kiniksa Pharmaceuticals" News Articles 1–25 of 10,000+

Extremely Relevant

Kiniksa Pharmaceuticals Announces Proposed Public Offering and Concurrent Private Placement

Kiniksa Pharmaceuticals (Nasdaq:KNSA) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa. As quoted in the … Continued The post Kiniksa Pharmaceuticals Announ...


Relevant

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

HAMILTON, Bermuda, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”, “we”, and “our”) announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering and its previously announced...

Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco, California. The presentation will be followed by a question and answer session th...


Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

HAMILTON, BERMUDA, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will be presenting at the 2018 Wells Fargo Healthcare Conference on Thursday, September 6th, 2018 at 8:00 a.m. Eastern Time at The Westin Copley Place in Boston, MA. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of ...

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement

HAMILTON, Bermuda, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional Class A common shares. All of the Class A common shares ...

Kiniksa completes concurrent public and private offerings, grosses $82mm

Kiniksa Pharmaceuticals Ltd. (treatments for autoimmune and inflammatory diseases) grossed $82mm through concurrent public an...

Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab

HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a clinical study of mavrilimumab in subjects with g...

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress

– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing into multiple chronic pruritic diseases, starting with a planned Phase 2a/2b in prurigo nodularis in Q1 2019– KPL-716 repeated-single-dose Phase 1b results expected in 2H 2019 HAMILTON, Bermuda, Nov. 01, 2018 (GLO...

Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress

– Rilonacept advancing toward pivotal Phase 3 clinical trial in 2H 2018 following recent End-of-Phase 2 communication with FDA – – KPL-716 single-dose Phase 1a/1b Last Subject Last Visit achieved; clinical trial data expected in Q3 2018 – – Mavrilimumab advancing toward Phase 2 clinical trial in 2H 2018; ex-U.S. IMPD/CTA filings ongoing; pre-IND meeting scheduled with FDA – – Co...

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

- Single-doses were well-tolerated and showed reduction in pruritus - - Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis - HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therap...

Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis

HAMILTON, Bermuda, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline consisting of five product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions, today announced that the U.S. Food and Drug Administration (FDA) requested additional information regarding...

Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

HAMILTON, Bermuda, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present clinical data for KPL-716, an investigational fully-human monocl...

$KNSA Announces Active U.S. Investigational New Drug Application for Mavrilimumab https://finance.yahoo.com/news/kiniksa-announces-active-u-investigational-123000419.html …

$KNSA Announces Active U.S. Investigational New Drug Application for Mavrilimumab https://finance.yahoo.com/news/kiniksa-announces-active-u-investigational-123000419.html …

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial

- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial, RHAPSODY, now actively recruiting and screening subjects HAMILTON, Bermuda, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company wi...

Kiniksa Pharmaceuticals Ltd KNSA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12092018] Prices from USD $250

SummaryKiniksa Pharmaceuticals Ltd Kiniksa Pharmaceuticals is a clinicalstage biopharmaceutical company focused on discovery, acquisition, development and commercialization of therapeutic medicines for the treatment of auto inflammatory and autoimmune diseases. Its pipeline product portfolio includes Rilonacept used for the treatment of recurrent pericarditis; Mavrilimumab, a monoclonal antibody f...

Botox Effect Lasts Longer At Higher Doses, TEVA Gets FDA Nod, KNSA On Watch

Today's Daily Dose brings you news about results from Allergan's clinical study evaluating higher doses of BOTOX Cosmetic; CEL-SCI's better capitalization, following exercise of warrants; Kiniksa's phase 1a/1b clinical trial of KPL-716 in moderate-to-severe atopic dermatitis, and FDA approval of Teva's preventive treatment of migraine.

AMAG Pharmaceuticals to Acquire Perosphere Pharmaceuticals

AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hematology with Perosphere’s next-generation anticoagulant reversal candidate ciraparantag (PER977). Ciraparantag is an intravenously-administered synthetic small molecule anticoagulant reversal agen...

Probably Relevant

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma appeared first on Drug Development Technology.

InMed Pharmaceuticals - Entering the clinic by the end of the year

Edison Investment Research - Pharmaceuticals & healthcare - InMed Pharmaceuticals: InMed recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis ...

GW Pharmaceuticals plc: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescr...

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Neuren Pharmaceuticals (ASX:NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. As quoted in the press releas...

Checkmate Pharmaceuticals Appoints Barry Labinger President & CEO

Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, where he was president and CEO. His experience also includes leadership positions at Human Genome Sciences, 3M Pharmaceuticals, and Immunex. Labinger is succeeding Arthur Krieg, who is shifting to [̷...

Telix Pharmaceuticals Limited: Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA

MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company foc...

Nuvo Pharmaceuticals to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals

NewsUpon closing of the Proposed Transaction, Nuvo would pay Aralez $110 million in cash,

M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals

Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m. Astellas made an upfront payment of $164.6m and has...Read More... The post M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals appeared first on Pharmaceutical Tech


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks